Page 8 - Tim Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Icepack | Jan. 28-Feb. 4 Let’s start with something frivolous for once: Philly football (because how serious can anybody on that team – front office or backfield be – what with the stupid decisions they’ve all made since their last Super Bowl win) and the hiring of young Nick Sirianni as the Philadelphia Eagles new head coach.  One, is there really a whiff of racism to be smelt and dealt among the Eagles executive branch, as is rumored, considering how longtime Eagles assistant head coach Duce Staley got passed over for the top job, not once, but, twice? The Duce rocks, and if he was...

Senti Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced that Dr. Tim Lu, the CEO of Senti Bio, will present a corporate overview at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 th at 2:35 p.m. ET. After Dr. Lu’s prepared remarks, Senti Bio will make the presentation available on its website. About Senti Bio Senti Bio is a next-generation therapeutics company that is developing gene circuits and programming cel...

(2) Senti Bio's gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors inclu...

(Getty Images) Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences. Nearly three years after its initial $53 million series A, Senti Bio now has now doubled its funding, adding Bayer’s VC arm into the mix and continuing in 2021 its ongoing mission to become a broad gene therapy player. Fierce 15 winner Senti Bio’s approach involves what it calls “gene circuits,” essentially tweaking a cell’s genetic code which can morph in order to address the severity of a disease, all the while limiting side effects. The Californi...